The IPO pipeline is filling up.
Everyone remains 100% focused on SpaceX – and it’s $1.75 trillion IPO. That’s why investors are rushing to secure shares ahead of the mega transaction.
Here’s how to claim SpaceX Pre-IPO shares before it starts trading.
Five companies are scheduled to go public this week — making it one of the busiest IPO windows of the year so far.
Keep reading for details on the 5 deals expected to start trading this week. But first – let’s look at the year-to-date IPO performance:
· 50 IPOs have priced in 2026
· $17.2 billion in total proceeds raised
· Average IPO return is 23%
That's a healthy market by any measure.
Now, here's what's on deck this week.
HawkEye 360 (HAWK) is the deal I'm watching most. The company operates a constellation of small satellites that collect radio frequency data — then uses AI analytics to detect, locate, and track signal emitters. Its customers are primarily in defense and intelligence.
The deal is priced at $24–$26 per share, targeting a $2.7 billion market cap and raising $400 million. Goldman and Morgan Stanley are leading it. Pricing is expected Wednesday.
Suja Life (SUJA) is the consumer play of the week. You probably know Suja — the cold-pressed juice brand you've seen at Whole Foods. The company also owns Vive Organic and Slice, covering wellness shots and functional sodas. They're raising $200 million at an $871 million valuation. One flag: the company carries a heavy debt load, and interest expense has been a drag on earnings.
Odyssey Therapeutics (ODTX) is a Phase 2 biotech focused on autoimmune diseases. Its lead drug targets ulcerative colitis. The deal is raising $225 million at an $845 million market cap, led by JP Morgan and TD Cowen. Pricing Thursday.
Mobia Medical (MOBI) has the most interesting product story of the group. The company's Vivistim system is the only FDA-approved device that uses vagus nerve stimulation to help stroke survivors recover arm function. It's a niche but differentiated play. Raising $150 million at a $549 million cap.
Rare Earths Americas (REA) is exploration-stage — no revenue yet — focused on heavy rare earth elements like neodymium and dysprosium used in permanent magnets. Small deal at $50 million. Higher risk, but the rare earths theme is getting attention given U.S. supply chain concerns.
The pipeline for upcoming IPOs is also deep. There are currently 41 non-SPAC IPOs filed and awaiting pricing, looking to raise $10.7 billion combined.
That doesn’t include confidential IPOs like SpaceX.
That deal will dwarf every other offering this year – with plans to raise +$75 billion at a $1.75 trillion valuation.
“Smart money” investors in Silicon Valley and on Wall Street are not waiting for the IPO. Instead, they’re investing right here before the stock starts trading. And you can too.
Ian Wyatt
Editor, IPO Watch